Fractyl Health (GUTS) said Tuesday that new preclinical data from its obesity candidate RJVA-002 showed 30% weight loss in mice after a single dose, with no adverse effects observed.

The company said the study used a diet-induced obesity model with humanized GIP receptors and demonstrated a dose-dependent reduction in body weight over five weeks, with weight loss still ongoing.

RJVA-002, the second candidate from its Rejuva Smart GLP-1 platform, expands its potential use from type 2 diabetes to obesity, the company said. It said RJVA-001 is set to begin human trials next year for type 2 diabetes.

Shares of the company were up less than 1% in recent Tuesday premarket activity.